Open access
Open access
Powered by Google Translator Translator

Vaccines

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

 

Large populational study finds prior SARS-CoV-2 infection reduces the risk of breakthrough infection following mRNA vaccination.

14 Nov, 2021 | 20:12h | UTC

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Commentaries:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Commentary on Twitter

 

Populational study in Qatar showed the effectiveness against SARS-CoV-2 Delta-induced severe, critical or fatal disease was 93.4% for the Pfizer vaccine and 96.1% for Moderna.

14 Nov, 2021 | 20:11h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Commentary on Twitter

 

SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study.

14 Nov, 2021 | 20:05h | UTC

News Release: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School

Original study: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology

 

Commentary from the author on Twitter (thread – click for more)

 

RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.

12 Nov, 2021 | 10:43h | UTC

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet

Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet

Related: WHO issues emergency use approval for India’s Covaxin.

 

Commentary on Twitter

 

Boosting immunity to COVID-19 vaccines – “New studies highlight the immunological benefits of COVID-19 vaccine boosters, but questions remain over how to best make use of a limited global supply”.

12 Nov, 2021 | 10:37h | UTC

Boosting immunity to COVID-19 vaccines – Nature Medicine

 

Map: The world according to covid vaccine coverage.

12 Nov, 2021 | 10:34h | UTC

The world according to covid vaccine coverage – The BMJ

 

Commentary on Twitter

 

WHO, CDC | Global progress against measles threatened amidst COVID-19 pandemic.

12 Nov, 2021 | 10:27h | UTC

News Release: Global progress against measles threatened amidst COVID-19 pandemic – World Health Organization

Report: Progress Toward Regional Measles Elimination — Worldwide, 2000–2020 – CDC Morbidity and Mortality Weekly Report

Commentary: Measles is a renewed global threat after 22 million babies missed their vaccines during the pandemic, CDC warns – CNN

 

Commentary on Twitter (thread – click for more)

 

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

10 Nov, 2021 | 07:24h | UTC

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age – New England Journal of Medicine

 

Commentary on Twitter

 

French health authority advises against Moderna Covid-19 vaccine for under 30s.

10 Nov, 2021 | 07:18h | UTC

French Health Authority Advises Against Moderna COVID-19 Vaccine for Under 30s – Reuters

See also: France advises against Moderna for under-30s over rare heart risk – Associated Press

Related: Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.

 

Commentary on Twitter

 

How protein-based COVID vaccines could change the pandemic.

9 Nov, 2021 | 01:41h | UTC

How protein-based COVID vaccines could change the pandemic – Nature

 

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines.

9 Nov, 2021 | 01:31h | UTC

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines – The Conversation

 

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.

7 Nov, 2021 | 20:29h | UTC

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination – Clinical Infectious Diseases

Related:

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Viewpoint | Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.

7 Nov, 2021 | 20:31h | UTC

Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA

 

[Not published yet] Chinese drug firm Sinovac says Covid-19 vaccine safe for children and babies as young as six months old.

7 Nov, 2021 | 20:32h | UTC

Chinese drug firm Sinovac says Covid-19 vaccine safe for children, babies as young as six months old; submits data to Hong Kong government – South China Morning Post

Related:

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 

COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.

7 Nov, 2021 | 20:27h | UTC

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety – Drug Safety

 

Germany offers booster shots to everyone amid ‘very worrying’ surge in cases.

7 Nov, 2021 | 20:22h | UTC

Germany offers booster shots to everyone amid ‘very worrying’ surge in cases – CNN

 

Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

5 Nov, 2021 | 09:59h | UTC

Original study: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 – Science

News release: Breakthrough Infection Study Compares Decline in Vaccine Effectiveness and Consequences for Mortality – Public Health Institute

 

Commentary on Twitter

 

Observational study showed J&J single shot vaccine had an effectiveness of 74% against symptomatic Covid-19.

4 Nov, 2021 | 10:08h | UTC

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19 – JAMA Network Open

Commentaries:

Single-Dose Ad26.COV2.S Vaccine—Room for Improvement – JAMA Network Open

Real-world study shows J&J COVID-19 vaccine 74% effective – CIDRAP

Related:

J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

[Preprint] Observational study finds single-dose Johnson & Johnson vaccine is 76.7% effective in preventing SARS-CoV-2 infection

RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351

 

WHO issues emergency use approval for India’s Covaxin.

4 Nov, 2021 | 10:11h | UTC

WHO issues emergency use listing for eighth COVID-19 vaccine – World Health Organization

Commentaries:

WHO Gives India’s Covaxin Approval, Opening the Door to COVAX distribution – Health Policy Watch

WHO green-lights India’s COVID vaccine as global cases rise – CIDRAP

 

Commentary on Twitter (thread – click for more)

 

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

4 Nov, 2021 | 10:06h | UTC

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Commentaries:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

 

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

4 Nov, 2021 | 09:58h | UTC

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study – The Lancet

Related:

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Commentary on Twitter

 

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.

3 Nov, 2021 | 10:09h | UTC

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm – The Lancet Infectious Diseases

Related:

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

 

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

3 Nov, 2021 | 10:11h | UTC

ACIP Presentation Slides: November 2-3, 2021 Meeting – Centers for Disease Control and Prevention

Commentaries:

CDC advisors give go-ahead to COVID-19 vaccines for young kids – CIDRAP

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11 – STAT

American Academy of Pediatrics Applauds CDC Advisory Committee’s Approval of Safe, Effective COVID-19 Vaccine for Children Ages 5-11

 

In Covid-19 vaccinated people, those with prior infection are likely to have more antibodies.

2 Nov, 2021 | 03:03h | UTC

News release: In Covid-19 Vaccinated People, Those with Prior Infection Likely to Have More Antibodies – Johns Hopkins Medicine

Original Article: Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection – JAMA

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.